Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL -1.95% EV-to-EBIT is -25.08 as of Aug. 11, 2026. The stock has 6 warning signs investors should review. Among 372 Biotechnology companies, Adlai Nortye ranks worse than 268816.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Adlai Nortye's Enterprise Value for the quarter that ended in Dec. 2025 was $75.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-34.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye EV-to-EBIT Related Terms
Adlai Nortye EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's EV-to-EBIT falls into.
Adlai Nortye's current Enterprise Value is $853.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-34.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a EV-to-EBIT of -25.08 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #999999 out of 372 companies in the Biotechnology industry.
Is Adlai Nortye's EV-to-EBIT too high?
Adlai Nortye's current EV-to-EBIT is -25.08. Based on the distribution chart, Adlai Nortye ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's EV-to-EBIT compare to REPL and SLDB?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #999999 out of 372 companies for EV-to-EBIT. This places Adlai Nortye in the lower half of its industry. The industry median EV-to-EBIT is 15.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.09, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current EV-to-EBIT is -25.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current EV-to-EBIT of -25.08. The current EV-to-EBIT is -25.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Adlai Nortye (ANL), the current EV-to-EBIT is -25.08 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
